DoW Pancreatic Cancer Research Program, Idea Development Award
This grant funds innovative, high-risk research projects with preliminary data to advance pancreatic cancer outcomes, with extra support for teams pairing experienced and early-career investigators; clinical trials are not allowed.
Funder: Dept. of the Army -- USAMRAA
Due Dates: July 7, 2026: Pre-application | October 7, 2026: Full application | October 13, 2026: End of application verification period
Funding Amounts: ~$9.9M total; up to $700,000 total costs (single PI) or $950,000 (Partnering PI Option), max 3 years.
Summary: Supports innovative, high-risk/high-reward research to accelerate progress in improving outcomes for individuals with pancreatic cancer; clinical trials are not allowed.
Key Information: Requires preliminary data; both domestic and foreign organizations eligible; Partnering PI option available for early-career investigators.
Description
This opportunity, offered by the Dept. of the Army through the U.S. Army Medical Research Acquisition Activity (USAMRAA) and the Congressionally Directed Medical Research Programs (CDMRP), supports innovative, high-risk/high-reward research in pancreatic cancer. The goal is to drive critical discoveries or major advancements that improve outcomes for individuals affected by pancreatic cancer. Projects must address at least one of the FY26 Pancreatic Cancer Research Program (PCARP) Focus Areas, which include early detection, risk characterization, supportive care, metabolic disruptions, tumor development, biomarkers, and new therapeutic targets.
Distinctive features include a requirement for preliminary data and the availability of a Partnering Principal Investigator (PI) Option, which allows an experienced PI to collaborate with an Early-Career Investigator for a higher funding cap. Clinical research studies are permitted, but clinical trials are not.
